about
Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesisThe molecular biology, biochemistry, and physiology of human steroidogenesis and its disordersThe syndrome of 17,20 lyase deficiencyWhy boys will be boys: two pathways of fetal testicular androgen biosynthesis are needed for male sexual differentiationHuman steroid biosynthesis for the oncologistBeyond T and DHT - novel steroid derivatives capable of wild type androgen receptor activationAndrogen biosynthesis in castration-resistant prostate cancerCopy number variation in the horse genomeCYP17 inhibitors for prostate cancer therapyTestosterone and erectile function: from basic research to a new clinical paradigm for managing men with androgen insufficiency and erectile dysfunction.Endocrine abnormalities in ring chromosome 11: a case report and review of the literatureAn improved micro-method for the measurement of steroid profiles by APPI-LC-MS/MS and its use in assessing diurnal effects on steroid concentrations and optimizing the diagnosis and treatment of adrenal insufficiency and CAH.The steroid metabolome of adrenarcheThe Activity of SN33638, an Inhibitor of AKR1C3, on Testosterone and 17β-Estradiol Production and Function in Castration-Resistant Prostate Cancer and ER-Positive Breast Cancer.Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancerMECHANISMS IN ENDOCRINOLOGY: The sexually dimorphic role of androgens in human metabolic disease.Androgenic potential of human fetal adrenals at the end of the first trimester.Management of the adult with congenital adrenal hyperplasia.Abiraterone acetate to lower androgens in women with classic 21-hydroxylase deficiency.New frontiers in androgen biosynthesis and metabolism.The transcriptomics of de novo androgen biosynthesis in prostate cancer cells following androgen reductionXenografting of human fetal testis tissue: a new approach to study fetal testis development and germ cell differentiation.Impact of androgen deprivation therapy on sexual functionRole of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolismCorrelation between genotype, phenotype and sex of rearing in 111 patients with partial androgen insensitivity syndrome.In humans, early cortisol biosynthesis provides a mechanism to safeguard female sexual developmentNew hormonal therapies for castration-resistant prostate cancer.The aldo-keto reductases (AKRs): Overview.The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer.Adrenal androgens and androgen precursors-definition, synthesis, regulation and physiologic actions.Adrenal steroidogenesis and congenital adrenal hyperplasia.Advantages and Limitations of Androgen Receptor-Based Methods for Detecting Anabolic Androgenic Steroid Abuse as Performance Enhancing Drugs.The next 150 years of congenital adrenal hyperplasia.Hormonal circadian rhythms in patients with congenital adrenal hyperplasia: identifying optimal monitoring times and novel disease biomarkersConsequences of POR mutations and polymorphisms.Pre-receptor regulation of the androgen receptorNADPH-cytochrome P450 oxidoreductase: roles in physiology, pharmacology, and toxicology.Germline predictors of androgen deprivation therapy response in advanced prostate cancerMinireview: Androgen metabolism in castration-resistant prostate cancer.Cortisol-Metabolizing Enzymes in Polycystic Ovary Syndrome.
P2860
Q24531477-7F230408-811C-46AF-93F9-88F39E35454CQ24613957-47469A8B-E23A-42E7-8AF5-7A85D5E161BBQ24614420-C040C92B-81A4-4A5D-9DF8-942470C99DFAQ24618043-FAF998D7-5993-46D8-B736-E1678FC3AF68Q26999384-1B8A4054-B0D5-47B3-BF53-BD562E47B07CQ27007208-6FAA48B5-E658-4143-8B9D-1224077D5A04Q27026044-247AE348-1933-4522-B0B6-891A6CF59B98Q27312309-46611EF2-44E8-40B0-88A8-3D7EB56339C1Q28298818-CF4E62FF-D661-46F6-A5AB-4376674C6C3DQ33276072-7AFE7145-C176-4E37-968F-2957F3FFDB08Q33427602-DF44FCAA-995B-4BA4-8F3B-5100B75FD46DQ33466843-35A1575C-82C5-4F55-9C3A-205B13313925Q33699331-C14954EF-684E-4A1C-8A1D-CF43CBD0162BQ33770742-6E1859B2-2602-4CEA-BA83-49B39961AE89Q33823702-38F14D50-C0D8-4AF6-BF4E-88C1B5DF78C1Q33904576-D64BC8DC-728B-4611-9002-96329949E9C8Q33917191-251F834A-3454-438D-8514-957C2E62A128Q33960872-7B61DAB6-8C81-4EB6-A8FF-B4271C124B9CQ33998980-F3F44FC4-8AF4-4CD7-9069-3FBB51351F33Q34100727-8F10999B-307D-4B4D-A6F2-6564D8376A68Q34127128-E777414C-FB50-43E5-A63B-94495EA7C259Q34129274-FD59BBCB-0507-47A9-92C2-5F4571BF7786Q34245932-EA4DFCBC-3AB2-4A77-A29B-C7BE80A17117Q34382405-5ACD7E60-8351-4BF0-B754-BB76C229AF10Q34427210-F96A7D0C-17B2-4A30-BC3D-AAF3D5722D5DQ34498916-2DC691BB-68A4-43D8-98F7-5BD7914C09E5Q35196715-2B82F9D3-9485-4374-95A2-A3B64708866EQ35305934-8DA8E597-55E1-4B88-BE88-D2F1EF4D62F4Q35553876-F4AE6C5E-B2C6-4636-B922-F0CA16E9FC2CQ35624417-97FB4740-01AE-4D4D-A671-B0608B4405C6Q35863921-A68A3D8E-C79D-4156-8902-02B0FD8AA6DAQ35964561-E14114F4-6586-4AC5-8C04-6511A2C223D4Q36055119-389B13D4-A1D4-4AD4-943E-A767146C4EA8Q36217821-F242402B-525F-4375-B616-D3676F9C41D9Q36248030-6A8A8B38-67A6-4650-B1D9-6F635CAA566DQ36426559-2FC55158-5C47-416F-BC1D-5D10B86F706AQ36497649-799CD0A5-2E29-45A8-8314-644D976BE4E7Q36512896-E6BEBAAE-0C7D-4766-A131-1716C71857A7Q36789277-639A1CDF-6788-4209-9A8A-649BF9C18AF0Q36878086-44590EF7-24E4-47FB-8C67-B6DEE02D5004
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The backdoor pathway to dihydrotestosterone.
@ast
The backdoor pathway to dihydrotestosterone.
@en
type
label
The backdoor pathway to dihydrotestosterone.
@ast
The backdoor pathway to dihydrotestosterone.
@en
prefLabel
The backdoor pathway to dihydrotestosterone.
@ast
The backdoor pathway to dihydrotestosterone.
@en
P1476
The backdoor pathway to dihydrotestosterone.
@en
P2093
Richard J Auchus
P304
P356
10.1016/J.TEM.2004.09.004
P577
2004-11-01T00:00:00Z